Study Title

Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types

Study Details

Description:

The aim of the project is to demonstrate superior detection ratio of [18F]AlF-FAPI-74 PET/CT compared to [18F]FDG PET/CT or conventional imaging in treatment-naïve, newly diagnosed patients with oesophagogastric adenocarcinoma (clinical T1-4N0-3M0) and pancreatic ductal adenocarcinoma (clinical T1-4N0-2M0-1) and describe the clinical utility of [18F]AlF-FAPI-74 PET/CT in oncological patients with a clinically challenging situation.

Sponsor:

KU Leuven

Contacts:

Karen Gerboes (Professor)

hiruz@uzgent.be

+32 9 332 05 30

Christopher Deroose (Professor)

deroose@azleuven.be

+32 1 643 37 15

Government Study Link:

NCT06782412 - Click here to see study on

ClinicalTrials.gov

Drug Details

[18F]AlF-FAPI-74

Isotope(s):

FLUORINE-18

Radioisotope: F-18

Theranostic Role: PET Imaging

T1/2 (Half-Life): 1.8 Hours

Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV

Energy: Eβ+ 635 keV

Range: N/A

Decay Daughters: O18 (Stable)

Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)

FLUORINE-18

Target(s):

[18F]FDG